SEC Form 4 · accession 0001209191-17-009300
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis T Williams
Officer — President, CEO and Chairman · Director
Period of report
Feb 7, 2017
Accepted (ET)
Feb 9, 2017 · 7:36 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Sep 1, 2016 | G | 22,416 | $0.00 | D | 406,411 | D | |
| Common StockF1 | Feb 7, 2017 | A | 16,875 | $0.00 | A | 423,286 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (right to buy)F2 | $45.38 | Feb 7, 2017 | A | 101,250 | A | — | Feb 6, 2027 | Common Stock | 101,250 | 101,250 | D |
Explanation of responses
- F1Represents shares of restricted stock, which will vest according to the following schedule: one-third (1/3) of the restricted stock will vest on each of February 5, 2018, 2019 and 2020, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.
- F2The shares underlying the option vest at a rate of one forty-eighth (1/48th) per month beginning on March 7, 2017, provided the reporting person provides services to Five Prime Therapeutics, Inc. through each such date.